- Home
- SDHC vs GPCR Comparison
SDHC vs GPCR Comparison
Compare SDHC & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHC
- GPCR
- Stock Information
- Founded
- SDHC 2008
- GPCR 2016
- Country
- SDHC United States
- GPCR United States
- Employees
- SDHC N/A
- GPCR N/A
- Industry
- SDHC
- GPCR
- Sector
- SDHC
- GPCR
- Exchange
- SDHC Nasdaq
- GPCR Nasdaq
- Market Cap
- SDHC 1.0B
- GPCR 1.1B
- IPO Year
- SDHC 2024
- GPCR 2023
- Fundamental
- Price
- SDHC $19.03
- GPCR $25.57
- Analyst Decision
- SDHC Hold
- GPCR Strong Buy
- Analyst Count
- SDHC 4
- GPCR 9
- Target Price
- SDHC $30.25
- GPCR $78.13
- AVG Volume (30 Days)
- SDHC 34.2K
- GPCR 1.2M
- Earning Date
- SDHC 05-14-2025
- GPCR 05-20-2025
- Dividend Yield
- SDHC N/A
- GPCR N/A
- EPS Growth
- SDHC N/A
- GPCR N/A
- EPS
- SDHC 1.81
- GPCR N/A
- Revenue
- SDHC $975,463,000.00
- GPCR N/A
- Revenue This Year
- SDHC $6.82
- GPCR N/A
- Revenue Next Year
- SDHC $11.61
- GPCR N/A
- P/E Ratio
- SDHC $10.54
- GPCR N/A
- Revenue Growth
- SDHC 27.57
- GPCR N/A
- 52 Week Low
- SDHC $17.03
- GPCR $13.22
- 52 Week High
- SDHC $39.50
- GPCR $62.74
- Technical
- Relative Strength Index (RSI)
- SDHC 46.12
- GPCR 59.07
- Support Level
- SDHC $18.56
- GPCR $25.06
- Resistance Level
- SDHC $19.46
- GPCR $27.50
- Average True Range (ATR)
- SDHC 0.80
- GPCR 1.66
- MACD
- SDHC 0.01
- GPCR 0.20
- Stochastic Oscillator
- SDHC 24.52
- GPCR 54.40
About SDHC Smith Douglas Homes Corp.
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. It is organized into eight geographical divisions which comprise two reportable segments. Its Southeast segment consists of Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of Alabama, Houston, and Nashville divisions.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.